GlassScriptPhysician profile
John David Cluley
NPI 1790915858
$4,035.78
in general payments reported to CMS, 2019-2025
30 companies · $854 in 2025
The $854 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $598 · 2020: $233 · 2021: $384 · 2022: $745 · 2023: $670 · 2024: $553 · 2025: $854.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,076.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,076.46 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,845.30 | 2019-2025 | Rinvoq, Mavyret, Skyrizi |
| Celgene Corporation | $352.04 | 2021-2024 | Zeposia |
| Gilead Sciences, INC. | $210.65 | 2019-2025 | |
| Qol Medical, LLC | $147.96 | 2019-2025 | Sucraid |
| Janssen Scientific Affairs, LLC | $146.74 | 2025 | Stelara, Tremfya |
| Pfizer INC. | $132.72 | 2019-2024 | |
| Regeneron Healthcare Solutions, INC. | $130.83 | 2023-2025 | Dupixent |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $126.37 | 2019-2024 | Xifaxan, Relistor |
| Daiichi Sankyo INC. | $113.52 | 2019-2022 | |
| Echosens North America, INC. | $110.08 | 2025 | Fibroscan |
| Janssen Biotech, INC. | $108.53 | 2019-2024 | Stelara |
| Ferring Pharmaceuticals INC. | $74.66 | 2020-2023 | Rebyota |
| Takeda Pharmaceuticals U.S.A., INC. | $64.81 | 2019-2021 | |
| Nestle Healthcare Nutrition INC. | $62.24 | 2022-2023 | |
| Aimmune Therapeutics, INC. | $49.42 | 2024 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Romark Laboratories, Lc | $46.52 | 2019 | |
| Amgen INC. | $40.84 | 2022 | |
| Lilly USA, LLC | $38.35 | 2024-2025 | Omvoh |
| Ironwood Pharmaceuticals, INC | $36.07 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $30.83 | 2019-2020 | |
| Johnson & Johnson Health Care Systems INC. | $28.74 | 2022-2023 | Stelara |
| Intercept Pharmaceuticals, INC. | $28.25 | 2021-2022 | |
| Ipsen Biopharmaceuticals, INC | $22.87 | 2025 | Iqirvo |
| Genzyme Corporation | $16.52 | 2022 | |
| Braintree Laboratories, INC. | $15.23 | 2022 | |
| Allergan, INC. | $15.16 | 2019 | |
| Vivus LLC | $14.88 | 2025 | Pancreaze |
| Phathom Pharmaceuticals, INC. | $14.52 | 2025 | Voquezna |
| Redhill Biopharma INC. | $11.13 | 2020 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$56,121.38 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Cluley listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.